Pharmacologic treatment of fibromyalgia: Towards chemical neuromodulation;Tratamiento farmacológico de la fibromialgia: hacia la neuromodulación química

Reumatologia Clinica

Volumn 5, Issue SUPPL. 2, 2009, Pages 27-31

  Collado, Antonio ^a   Conesa, Arantxa ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Fibromyalgia; Neuromodulation; Treatment

Indexed keywords

AMINE; ANALGESIC AGENT;

ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; DRUG MECHANISM; FIBROMYALGIA; HUMAN; NEUROMODULATION; NOCICEPTION; SYMPTOM; REVIEW;

EID: 67651102621     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2009.04.003     Document Type: Article

References (49)

1. Price D.D., and Staud R. Neurobiology of fibromyalgia syndrome. J Rheumatol 32 (2005) 22-28
2. Williams D.A., and Gracely R.H. Biology and therapy of fibromyalgia. Functional magnetic resonance imaging findings in fibromyalgia. Arthritis Res Ther 8 (2006) 224
3. Deus J., Pujol J., and Bofill J. Resonancia magnética funcional de la respuesta cerebral al dolor en pacientes con diagnóstico de fibromialgia. Psiq Biol 13 (2006) 39-46
4. Yunus M.B. The concept of central sensitivity syndromes. In: Wallace D.J., and Clauw D.J. (Eds). Fibromyalgia and other central syndromes (2005), Lippincott Williams & Wilkins, Philadelphia 29-44
5. Russell I.J., Orr M.D., Littman B., Vipraio G.A., Alboukrek D., Michalek J.E., et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37 (1994) 1593-1601
6. Vaeroy H., Helle R., Forre O., Kass E., and Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 32 (1998) 21-26
7. Giovengo S.L., Russell I., and Larson A. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 26 (1999) 1564-1569
8. Sarchielli P., Mancini M.L., Floridi A., Coppola F., Rossi C., Nardi K., et al. Increased levels of neurotrophins are not specific for chronic migraine: Evidence from primary fibromyalgia syndrome. J Pain 8 (2007) 737-745
9. Sarchielli P., Di Filippo M., Nardi K., and Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 11 (2007) 343-351
10. Collado A., Valdés M., Bargallo N., Vázquez M., Ramis M., Gómez E., et al. Incremento de los compuestos de glutamato en el cerebro de los pacientes con fibromialgia: un estudio mediante resonancia espectroscópica. Reumatol Clin 5 (2009) 7-8
11. Harris R.E., Sundgren P.C., Pang Y., Hsu M., Petrou M., Kim S.H., et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis and Rheum 58 (2008) 903-907
12. Desmeules J.A., Cedraschi C., Rapiti E., Baumgartner E., Finckh A., Cohen P., et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 48 (2003) 1420-1429
13. Russell I.J., Vaeroy H., Javors M., and Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35 (1992) 550-556
14. Julien N., Goffaux P., Arsenault P., and Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114 (2005) 295-302
15. Wood P.B., Patterson J.C., Sunderland J.J., Tainter K.H., Glabus M.F., and Lilien D.L. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study. Pain 8 (2007) 51-58
16. Wood P.B., Schweinhardt P., Jaeger E., Dagher A., Hakyemez H., Rabiner E.A., et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 25 (2007) 3576-3582
17. Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev Neurother 8 (2008) 781-797
18. Harris R.E., Clauw D.J., Scott D.J., McLean S.A., Gracely R.H., and Zubieta J.K. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 27 (2007) 10000-10006
19. Collado A., Alijotas J., Benito P., Alegre C., Romera M., Sañudo I., et al. Documento de consenso sobre el diagnóstico y tratamiento de la fibromialgia en Cataluña. Med Clin (Barc) 118 (2002) 745-749
20. Rivera J., Alegre-De Miguel C., Ballina J., Carbonell J., Carmona L., Castel B., et al. Documento de consenso de la Sociedad Española de Reumatología sobre la fibromialgia. Reumatol Clin 2 (2006) S38-S49
21. Carville S.F., Arendt-Nielsen S., Bliddal H., Blotman F., Branco J.C., Buskila D., et al. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 67 (2008) 536-541
22. Goldenberg D.L., Burckhardt C., and Crofford L. Management of fibromyalgia syndrome. JAMA 292 (2004) 2388-2395
23. Arnold L.M., and Keck P.E. Antidepressant treatment of fibromyalgia: A meta-analysis and review. Psychosomatics 41 (2000) 104-113
24. O'Malley P.G., Balden E., Tomkins G., Santoro J., Kroenke K., and Jackson J.L. Treatment of fibromyalgia with antidepressants: A meta-analysis. J Gen Intern Med 15 (2000) 659-666
25. Goldenberg D., Mayskiy M., Mossey C., Ruthazer R., and Schmid C. A randomized double blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39 (1996) 1852-1859
26. Tofferi J.K., Jackson J.Y., and O'Malley P.G. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum 51 (2004) 9-13
27. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50 (2004) 2974-2984
28. Arnold L.M., Rosen A., Pritchett Y.L., D'Souza D.N., Goldstein D.J., Iyengar S., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119 (2005) 5-15
29. Russell I.J., Mease P.J., Smith T.R., Kajdasz D.K., Wohlreich M.M., Detke M.J., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136 (2008) 432-444
30. Vitton O., Gendreau M., Kranzler J., and Rao G. A double blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19 (2004) 27-35
31. Gendreau R.M., Thorn M.D., Gendreau J.F., Kranzler J.D., Ribeiro S., Gracely R.H., et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32 (2005) 1975-1985
32. Clauw D.J., Mease P., Palmer R.H., Gendreau R.M., and Wang Y. Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 30 (2008) 1988-2004
33. Mease P.J., Clauw D.J., Gendreau R.M., Rao S.G., Kranzler J., Chen W., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 36 (2009) 398-409
34. Biasi G., Manca S., Manganelli S., and Marcolongo R. Tramadol in the fibromyalgia syndrome: A controlled clinical trial versus placebo. Int J Clin Pharmacol Res 18 (1998) 13-19
35. Bennett R.M., Kamin M., Karin R., and Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain. Am J Med 114 (2003) 537-545
36. Bennett R.M., Schein J., Kosinski M.R., Hewitt D.J., Jordan D.M., and Rosenthal N.R. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 53 (2005) 519-527
37. Holman A.J., and Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52 (2005) 2495-2505
38. Scharf M.B., Baumann M., and Berkowitz D.V. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 30 (2003) 1070-1074
39. Russell I.J., Perkins A.T., Michalek J.E., and Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 60 (2009) 299-309
40. Dooley D.J., Taylor C.P., Donevan S., and Feltner D. Ca2+ channel α2δligands: Novel modulators of neurotransmission. Trends Pharmacol Sci 28 (2007) 75-82
41. Arnold L.M., Goldenberg D.L., Stanford S.B., Lalonde J.K., Sandhu H.S., Keck P.E., et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo controlled, multicenter trial. Arthritis Rheum 56 (2007) 1336-1344
42. Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
43. Arnold L.M., Russell I.J., Diri E.W., Duan W.R., Young Jr. J.P., Sharma U., et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9 (2008) 792-805
44. Mease P.J., Russell I.J., Arnold L.M., Florian H., Young J.P., Martin S.A., et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35 (2008) 502-514
45. Crofford L.J., Mease P.J., Simpson S.L., Young J.P., Martin S.A., Haig J.M., et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136 (2008) 419-431
46. Sörenson J., Bengtsson A., Ahlner J., Henriksson K.G., Ekselius L., and Bengtsson M. Fibromyalgia: Are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 24 (1997) 1615-1621
47. Graven-Nielsen T., Aspegren Kendall S., Henriksson K.G., Bengtsson M., Sörensen J., Johnson A., et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 85 (2000) 483-491
48. Cohen S.P., Verdolin M.H., Chang A.S., Kurihara C., Morlando B.J., and Mao J. The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain 7 (2006) 391-398
49. Bennett R.M., Jones J., Turk D.C., Russell I.J., and Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 9 (2007) 8-27